These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 22675821)

  • 1. [Resistance to treatment in movement disorders].
    Vingerhoets FJ; Burkhard PR
    Rev Med Suisse; 2012 May; 8(339):926-9. PubMed ID: 22675821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Current treatment strategies for Parkinson's disease].
    Südmeyer M; Wojtecki L; Schnitzler A
    Fortschr Neurol Psychiatr; 2011 Dec; 79(12):733-43. PubMed ID: 22161168
    [No Abstract]   [Full Text] [Related]  

  • 3. The Choice Between Advanced Therapies for Parkinson's Disease Patients: Why, What, and When?
    Dijk JM; Espay AJ; Katzenschlager R; de Bie RMA
    J Parkinsons Dis; 2020; 10(s1):S65-S73. PubMed ID: 32651333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus.
    De Gaspari D; Siri C; Landi A; Cilia R; Bonetti A; Natuzzi F; Morgante L; Mariani CB; Sganzerla E; Pezzoli G; Antonini A
    J Neurol Neurosurg Psychiatry; 2006 Apr; 77(4):450-3. PubMed ID: 16543520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Duodenale levodopa and apomorphine infusion for motor complications in advanced Parkinson's disease].
    Antonini A; Jost WH
    Fortschr Neurol Psychiatr; 2018 Sep; 86(S 01):S5-S9. PubMed ID: 30107620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Motor features and response to oral levodopa in patients with Parkinson's disease under continuous dopaminergic infusion or deep brain stimulation.
    Elia AE; Dollenz C; Soliveri P; Albanese A
    Eur J Neurol; 2012 Jan; 19(1):76-83. PubMed ID: 21645174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson's disease.
    Clarke CE; Worth P; Grosset D; Stewart D
    Parkinsonism Relat Disord; 2009 Dec; 15(10):728-41. PubMed ID: 19805000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment possibilities in advanced Parkinson's disease].
    Takáts A; Nagy H; Radics P; Tóth A; Tamás G
    Ideggyogy Sz; 2013 Nov; 66(11-12):365-71. PubMed ID: 24555235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias.
    Stocchi F; Nordera G; Marsden CD
    Clin Neuropharmacol; 1997 Apr; 20(2):95-115. PubMed ID: 9099462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Excellent response to apomorphine in Parkinsonism with optic atrophy unresponsive to oral antiparkinsonian medication.
    Deutschländer A; Asmus F; Marelli E; Klopstock T; Gasser T; Bötzel K
    Mov Disord; 2006 Sep; 21(9):1523-5. PubMed ID: 16755578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Movement Disorders: What Are You Doing? What Can We Do?].
    Oertel MF; Baumann CR; Stieglitz LH
    Praxis (Bern 1994); 2020 Apr; 109(6):433-437. PubMed ID: 32345180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deep brain stimulation for movement disorders: what counts in the end is the end result.
    Warnke P
    J Neurol Neurosurg Psychiatry; 2014 May; 85(5):474. PubMed ID: 24108058
    [No Abstract]   [Full Text] [Related]  

  • 13. [The concept of continuous dopaminergic stimulation in the treatment of late stages of Parkinson's disease].
    Titova NV; Katunina EA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(12):105-12. PubMed ID: 24596973
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatments for Parkinson disease--past achievements and current clinical needs.
    Poewe W
    Neurology; 2009 Feb; 72(7 Suppl):S65-73. PubMed ID: 19221317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D; Hanssens Y; Northway MG
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. History, applications, and mechanisms of deep brain stimulation.
    Miocinovic S; Somayajula S; Chitnis S; Vitek JL
    JAMA Neurol; 2013 Feb; 70(2):163-71. PubMed ID: 23407652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes using ClearPoint interventional MRI for deep brain stimulation lead placement in Parkinson's disease.
    Ostrem JL; Ziman N; Galifianakis NB; Starr PA; Luciano MS; Katz M; Racine CA; Martin AJ; Markun LC; Larson PS
    J Neurosurg; 2016 Apr; 124(4):908-16. PubMed ID: 26495947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome of young onset Parkinson's disease after subthalamic stimulation--a cross-sectional study.
    Tsai ST; Hung HY; Hsieh TC; Lin SH; Lin SZ; Chen SY
    Clin Neurol Neurosurg; 2013 Oct; 115(10):2082-7. PubMed ID: 23916724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The treatment of movement disorders by deep brain stimulation.
    Yu H; Neimat JS
    Neurotherapeutics; 2008 Jan; 5(1):26-36. PubMed ID: 18164481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Deep brain stimulation for movement disorders: indications, results and complications].
    Fleury V; Vingerhoets F; Horvath J; Pollak P; Burkhard P
    Rev Med Suisse; 2015 Apr; 11(472):962, 964-7. PubMed ID: 26062221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.